MAPT and Alzheimer disease: Additionally, a biomarker known as Alz-Tau® has been developed to effectively differentiate AD patients from healthy individuals by analyzing the ratio of high molecular weight Tau (HMWTau) to low molecular weight Tau (LMWTau) in platelets (Marizzoni et al., 2023).